50 results on '"Fiorentino, Michelangelo"'
Search Results
2. Real-time Augmented Reality Three-dimensional Guided Robotic Radical Prostatectomy: Preliminary Experience and Evaluation of the Impact on Surgical Planning
- Author
-
Schiavina, Riccardo, Bianchi, Lorenzo, Lodi, Simone, Cercenelli, Laura, Chessa, Francesco, Bortolani, Barbara, Gaudiano, Caterina, Casablanca, Carlo, Droghetti, Matteo, Porreca, Angelo, Romagnoli, Daniele, Golfieri, Rita, Giunchi, Francesca, Fiorentino, Michelangelo, Marcelli, Emanuela, Diciotti, Stefano, and Brunocilla, Eugenio
- Published
- 2021
- Full Text
- View/download PDF
3. Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma
- Author
-
Davidsson, Sabina, Fiorentino, Michelangelo, Giunchi, Francesca, Eriksson, Margareta, Erlandsson, Ann, Sundqvist, Pernilla, and Carlsson, Jessica
- Published
- 2020
- Full Text
- View/download PDF
4. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets
- Author
-
Caliò, Anna, Brunelli, Matteo, Segala, Diego, Pedron, Serena, Remo, Andrea, Ammendola, Serena, Munari, Enrico, Pierconti, Francesco, Mosca, Alessandra, Bollito, Enrico, Sidoni, Angelo, Fisogni, Simona, Sacco, Cosimo, Canu, Luisa, Sentinelli, Steno, Fraccon, Anna Paola, Fiorentino, Michelangelo, Scott, Cathryn, Milella, Michele, Porta, Camillo, Argani, Pedram, and Martignoni, Guido
- Published
- 2020
- Full Text
- View/download PDF
5. PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes
- Author
-
Davidsson, Sabina, Carlsson, Jessica, Giunchi, Francesca, Harlow, Alyssa, Kirrander, Peter, Rider, Jennifer, Fiorentino, Michelangelo, and Andrén, Ove
- Published
- 2019
- Full Text
- View/download PDF
6. The Metabolic Landscape of Prostate Cancer
- Author
-
Giunchi, Francesca, Fiorentino, Michelangelo, and Loda, Massimo
- Published
- 2019
- Full Text
- View/download PDF
7. Beta-Catenin Alterations in Postchemotherapy Yolk Sac Tumor, Postpubertal-Type With Enteroblastic Features.
- Author
-
Surucu, Ahmet, de Biase, Dario, Ricci, Costantino, di Sciascio, Luisa, Collins, Katrina, Idrees, Muhammad T., Ebare, Kingsley, Fiorentino, Michelangelo, Bridge, Julia A., Ulbright, Thomas M., and Acosta, Andres M.
- Published
- 2024
- Full Text
- View/download PDF
8. Antitissue transglutaminase antibodies' normalization after starting a gluten-free diet in a large population of celiac children-a real-life experience.
- Author
-
Sbravati, Francesca, Cosentino, Anita, Lenzi, Jacopo, Fiorentino, Michelangelo, Ambrosi, Francesca, Salerno, Angela, Di Biase, Annarita, Righi, Beatrice, Brusa, Sandra, Valin, Paola Sogno, Bruni, Laura, Battistini, Barbara, Pagano, Sara, Grondona, Ana Gabriela, Labriola, Flavio, and Alvisi, Patrizia
- Abstract
Few data are available regarding the trend of IgA anti-transglutaminase antibodies (TGA-IgA) in children with celiac disease (CD) on a gluten-free diet (GFD). Our aim is to examine the normalization time of CD serology in a large pediatric population, and its predictors. We retrospectively evaluated the normalization time of TGA-IgA and its predictive factors (age, sex, ethnicity, symptoms, associated diabetes/thyroiditis, Marsh stage, TGA-IgA and endomysial antibody levels at diagnosis, diet adherence), in 1024 children diagnosed from 2000 to 2019 in three pediatric Italian centers, on a GFD. TGA-IgA remission was reached in 67,3%, 80,7%, 89,8% and 94,9% after 12, 18, 24 and 36 months from starting a GFD, respectively (median time = 9 months). TGA-IgA >10´upper limit of normal at diagnosis (HR = 0.56), age 7–12 years old (HR = 0.83), poor compliance to diet (HR = 0.69), female sex (HR = 0.82), non-Caucasian ethnicity (HR = 0.75), and comorbidities (HR = 0.72) were independent factors significantly associated with longer time to normalization. Our population is the largest in the literature, with the majority of patients normalizing CD serology within 24 months from starting a GFD. We suggest a special attention to patients with comorbidities, language barriers or age 7–12 years for a proper management and follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Endothelial cell differentiation in hepatocellular adenomas: implications for histopathological diagnosis
- Author
-
Gouysse, Géraldine, Frachon, Sophie, Hervieu, Valérie, Fiorentino, Michelangelo, d'Errico, Antonia, Dumortier, Jérôme, Boillot, Olivier, Partensky, Christian, Grigioni, Walter F., and Scoazec, Jean-Yves
- Published
- 2004
- Full Text
- View/download PDF
10. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
- Author
-
Dall'Olio, Filippo G., Gelsomino, Francesco, Conci, Nicole, Marcolin, Laura, De Giglio, Andrea, Grilli, Giada, Sperandi, Francesca, Fontana, Francesca, Terracciano, Mario, Fragomeno, Benedetta, Tober, Nastassja, Manferrari, Giulia, Brocchi, Stefano, Golfieri, Rita, Fiorentino, Michelangelo, and Ardizzoni, Andrea
- Published
- 2021
- Full Text
- View/download PDF
11. Helicobacter pyloriiseroprevalence in hepatitis C virus positive patients with cirrhosis
- Author
-
Pellicano, Rinaldo, Leone, Nicola, Berrutti, Mara, Cutufia, Miguel Angel, Fiorentino, Michelangelo, Rizzetto, Mario, and Ponzetto, Antonio
- Published
- 2000
- Full Text
- View/download PDF
12. Immune checkpoint inhibitors for metastatic bladder cancer.
- Author
-
Massari, Francesco, Di Nunno, Vincenzo, Cubelli, Marta, Santoni, Matteo, Fiorentino, Michelangelo, Montironi, Rodolfo, Cheng, Liang, Lopez-Beltran, Anto, Battelli, Nicola, and Ardizzoni, Andrea
- Abstract
Chemotherapy has represented the standard therapy for unresectable or metastatic urothelial carcinoma for more than 20 years. The growing knowledge of the interaction between tumour and immune system has led to the advent of new classes of drugs, the immune-checkpoints inhibitors, which are intended to change the current scenario. To date, immunotherapy is able to improve the overall responses and survival. Moreover, thanks to its safety profile immune-checkpoint inhibitors could be proposed also to patients unfit for standard chemotherapy. No doubts that these agents have started a revolution expected for years, but despite this encouraging results it appears clear that not all subjects respond to these agents and requiring the development of reliable predictive response factors able to isolate patients who can more benefit from these treatments as well as new strategies aimed to improve immunotherapy clinical outcome. In this review we describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 4) inhibitors in urothelial carcinoma focusing our attention on the developing new immune-agents and combination strategies with immune-checkpoint inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.
- Author
-
Ciccarese, Chiara, Massari, Francesco, Iacovelli, Roberto, Fiorentino, Michelangelo, Montironi, Rodolfo, Di Nunno, Vincenzo, Giunchi, Francesca, Brunelli, Matteo, and Tortora, Giampaolo
- Abstract
Prostate cancer (PCa) shows a broad spectrum of biological and clinical behavior, which represents the epiphenomenon of an extreme genetic heterogeneity. Recent genomic profiling studies have deeply improved the knowledge of the genomic landscape of localized and metastatic PCa. The AR and PI3K/Akt/mTOR signaling pathways are the two most frequently altered, representing therefore interestingly targets for therapy. Moreover, somatic or germline aberrations of DNA repair genes (DRGs) have been observed at high frequency, supporting the potential role of platinum derivatives and PARP inhibitors as effective therapeutic strategies. In the future, the identification of driver mutations present at a specific stage of the disease, the classification PCa based on specific molecular alterations, and the selection of the most appropriate therapy based on biomarkers predictors of response represent the foundations for an increasingly more accurate personalized medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. The prospect of precision therapy for renal cell carcinoma.
- Author
-
Ciccarese, Chiara, Brunelli, Matteo, Montironi, Rodolfo, Fiorentino, Michelangelo, Iacovelli, Roberto, Heng, Daniel, Tortora, Giampaolo, and Massari, Francesco
- Abstract
The therapeutic landscape of renal cell carcinoma (RCC) has greatly expanded in the last decade. From being a malignancy orphan of effective therapies, kidney cancer has become today a tumor with several treatment options. Renal cell carcinoma (RCC) is a metabolic disease, being characterized by the dysregulation of metabolic pathways involved in oxygen sensing (VHL/HIF pathway alterations and the subsequent up-regulation of HIF-responsive genes such as VEGF, PDGF, EGF, and glucose transporters GLUT1 and GLUT4, which justify the RCC reliance on aerobic glycolysis), energy sensing (fumarate hydratase-deficient, succinate dehydrogenase-deficient RCC, mutations of HGF/MET pathway resulting in the metabolic Warburg shift marked by RCC increased dependence on aerobic glycolysis and the pentose phosphate shunt, augmented lipogenesis, and reduced AMPK and Krebs cycle activity) and/or nutrient sensing cascade (deregulation of AMPK-TSC1/2-mTOR and PI3K-Akt-mTOR pathways). In this complex scenario it is important to find prognostic and predictive factors that can help in decision making in the treatment of mRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.
- Author
-
Graff, Rebecca E., Pettersson, Andreas, Lis, Rosina T., Ahearn, Thomas U., Markt, Sarah C., Wilson, Kathryn M., Rider, Jennifer R., Fiorentino, Michelangelo, Finn, Stephen, Kenfield, Stacey A., Loda, Massimo, Giovannucci, Edward L., Rosner, Bernard, and Mucci, Lorelei A.
- Subjects
PROTEIN metabolism ,DIET therapy for cancer patients ,CONDIMENTS ,CONFIDENCE intervals ,STATISTICAL correlation ,EPIDEMIOLOGICAL research ,IMMUNOHISTOCHEMISTRY ,INGESTION ,LONGITUDINAL method ,LYCOPENE ,MEDICAL personnel ,MEN'S health ,MOLECULAR biology ,MULTIVARIATE analysis ,NUTRITION ,NUTRITIONAL assessment ,PROBABILITY theory ,PROSTATECTOMY ,PROSTATE tumors ,QUESTIONNAIRES ,RESEARCH funding ,STATISTICAL hypothesis testing ,TOMATOES ,TUMOR classification ,PROSTATE-specific antigen ,GENOMICS ,PROPORTIONAL hazards models ,FOOD diaries ,DATA analysis software ,MICROARRAY technology ,DESCRIPTIVE statistics ,ODDS ratio ,GENETICS ,TUMOR risk factors - Abstract
Background: There is limited evidence that supports etiologically distinct molecular subtypes of prostate cancer, the identification of which may improve prevention. Given their antioxidant properties, we hypothesized that lycopene and tomato sauce may be especially protective against diseases harboring the common gene fusion trans-membrane protease, serine 2 (TMPRSS2):v-ets avian erythroblastosis virus E26 oncogene homolog (ERG). Objective: We aimed to examine associations between estimated lycopene and tomato sauce intake and the risk of prostate cancer defined by ERG protein expression subtype. Design: Our study population consisted of a prospective cohort of 46,719 men from the Health Professionals Follow-Up Study. TMPRSS2:ERG was assessed by ERG immunohistochemistry on tumor tissue microarrays constructed from radical prostatectomy specimens. We used multivariable competing risk models to calculate HRs and 95% CIs for the risk of ERG-positive and, separately, ERG-negative disease. We implemented inverse probability weighting to account for evaluating ERG status only in surgically treated cases. Results: During 23 y of follow-up, 5543 men were diagnosed with prostate cancer, among whom 884 were assayed for ERG (426 ERG-positive). With inclusion of only the latter cases, increasing cumulative average tomato sauce intake was associated with a decreased risk of prostate cancer overall (≥2 servings/wk compared with <1 serving/mo; multivariable HR: 0.70; 95% CI: 0.52, 0.95; P-trend = 0.002). With respect to molecular subtypes, cumulative average tomato sauce intake was associated with a decreased risk of ERG-positive disease (HR: 0.54; 95% CI: 0.37, 0.81; P-trend = 0.004) but not with ERG-negative disease (HR: 0.96; 95% CI: 0.62, 1.50; P-trend = 0.10) (P-heterogeneity = 0.04). Increasing quintiles of lycopene intake were associated with a decreased risk of both subtypes (P-heterogeneity = 0.79). Inverse probability weighting did not materially change the results. Conclusions: Our results lend some support to the hypothesis that prostate cancers that harbor TMPRSS2:ERG may be etiologically distinct from fusion-negative cancers. In particular, tomato sauce consumption may play a role in reducing TMPRSS2:ERG-positive disease. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. MicroRNA profiling of primary pulmonary enteric adenocarcinoma shows similarity with lung cancer and pancreatic cancer
- Author
-
Garajová, Ingrid, Funel, Niccola, Fiorentino, Michelangelo, Agostini, Valentina, Ferracin, Manuela, Negrini, Massimo, Frassineti, Giovanni Luca, Biasco, Guido, and Giovannetti, Elisa
- Published
- 2015
- Full Text
- View/download PDF
17. The meaning of tissue and serum HCV RNA quantitation in hepatitis C recurrence after liver transplantation: A retrospective study.
- Author
-
Vasuri, Francesco, Morelli, Maria Cristina, Gruppioni, Elisa, Fiorentino, Michelangelo, Ercolani, Giorgio, Cescon, Matteo, Pinna, Antonio Daniele, Grigioni, Walter Franco, and D’Errico-Grigioni, Antonia
- Abstract
Abstract: Background: While the role of serum HCV RNA quantitation in hepatitis C virus recurrence after liver transplantation is well established, the meaning of HCV RNA tissue quantitation is largely unclear, and no correlations with recipient outcome have been investigated yet. Aims: To assess the predictive value, and a possible prognostic role, of tissue and serum HCV RNA in first post-transplant biopsies. Methods: We retrospectively reviewed the first post-transplant biopsies of 83 recipients. Tissue and serum HCV RNA was quantitated by RT-PCR, and compared with serum, clinical and histological data. Results: HCV RNA quantitation allowed us to categorise recipients into three different risk groups: (1) tissue HCV RNA≤1.5IU/ng with any serum HCV RNA; (2) tissue HCV RNA>1.5IU/ng and serum HCV RNA<40×10
6 copies/mL; (3) tissue HCV RNA>1.5IU/ng and serum HCV RNA≥40×106 copies/mL. Hepatitis C virus recurrence rates in the three groups were 68%, 91% and 100% (P =0.004); hepatitis C virus-related mortality was 0%, 14% and 45% respectively (P <0.001). Conclusions: This preliminary study on serum and tissue HCV RNA quantitation allows recipient “stratification” in prognostic groups, which could be applicable in the future for timely antiviral treatment and/or immunosuppression modulation. [Copyright &y& Elsevier]- Published
- 2013
- Full Text
- View/download PDF
18. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer.
- Author
-
Davidsson, Sabina, Ohlson, Anna-Lena, Andersson, Swen-Olof, Fall, Katja, Meisner, Allison, Fiorentino, Michelangelo, Andrén, Ove, and Rider, Jennifer R
- Published
- 2013
- Full Text
- View/download PDF
19. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer.
- Author
-
Davidsson, Sabina, Ohlson, Anna-Lena, Andersson, Swen-Olof, Fall, Katja, Meisner, Allison, Fiorentino, Michelangelo, Andrén, Ove, and Rider, Jennifer R
- Published
- 2013
- Full Text
- View/download PDF
20. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β-catenin in prostate cancer.
- Author
-
Fiorentino, Michelangelo, Zadra, Giorgia, Palescandolo, Emanuele, Fedele, Giuseppe, Bailey, Dyane, Fiore, Christopher, Nguyen, Paul L., Migita, Toshiro, Zamponi, Raffaella, Di Vizio, Dolores, Priolo, Carmen, Sharma, Chandan, Wanling Xie, Hemler, Martin E., Mucci, Lorelei, Giovannucci, Edward, Finn, Stephen, and Loda, Massimo
- Published
- 2008
- Full Text
- View/download PDF
21. Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins.
- Author
-
Rihawi, Karim, Cinausero, Marika, Fiorentino, Michelangelo, Salvagni, Stefania, Brocchi, Stefano, and Ardizzoni, Andrea
- Published
- 2018
- Full Text
- View/download PDF
22. The Use of Augmented Reality to Guide the Intraoperative Frozen Section During Robot-assisted Radical Prostatectomy.
- Author
-
Bianchi, Lorenzo, Chessa, Francesco, Angiolini, Andrea, Cercenelli, Laura, Lodi, Simone, Bortolani, Barbara, Molinaroli, Enrico, Casablanca, Carlo, Droghetti, Matteo, Gaudiano, Caterina, Mottaran, Angelo, Porreca, Angelo, Golfieri, Rita, Romagnoli, Daniele, Giunchi, Francesca, Fiorentino, Michelangelo, Piazza, Pietro, Puliatti, Stefano, Diciotti, Stefano, and Marcelli, Emanuela
- Subjects
- *
RADICAL prostatectomy , *SURGICAL margin , *AUGMENTED reality , *SURGICAL robots , *MAGNETIC resonance imaging , *GLEASON grading system , *PROSTATECTOMY - Abstract
Multiparametric magnetic resonance imaging (mpMRI) can guide the surgical plan during robot-assisted radical prostatectomy (RARP), and intraoperative frozen section (IFS) can facilitate real-time surgical margin assessment. To assess a novel technique of IFS targeted to the index lesion by using augmented reality three-dimensional (AR-3D) models in patients scheduled for nerve-sparing RARP (NS-RARP). Between March 2019 and July 2019, 20 consecutive prostate cancer patients underwent NS-RARP with IFS directed to the index lesion with the help of AR-3D models (study group). Control group consists of 20 patients matched with 1:1 propensity score for age, clinical stage, Prostate Imaging Reporting and Data System score v2, International Society of Urological Pathology grade, prostate volume, NS approach, and prostate-specific antigen in which RARP was performed by cognitive assessment of mpMRI. In the study group, an AR-3D model was superimposed to the surgical field to guide the surgical dissection. Tissue sampling for IFS was taken in the area in which the index lesion was projected by AR-3D guidance. Chi-square test, Student t test, and Mann-Whitney U test were used to compare, respectively, proportions, means, and medians between the two groups. Patients in the AR-3D group had comparable preoperative characteristics and those undergoing the NS approach were referred to as the control group (all p ≥ 0.06). Overall, positive surgical margin (PSM) rates were comparable between the two groups; PSMs at the level of the index lesion were significantly lower in patients referred to AR-3D guided IFS to the index lesion (5%) than those in the control group (20%; p = 0.01). The novel technique of AR-3D guidance for IFS analysis may allow for reducing PSMs at the level of the index lesion. Augmented reality three-dimensional guidance for intraoperative frozen section analysis during robot-assisted radical prostatectomy facilitates the real-time assessment of surgical margins and may reduce positive surgical margins at the index lesion. We proposed a novel technique of augmented reality three-dimensional (AR-3D) guided intraoperative frozen section (IFS) for real-time assessment of surgical margins during robot-assisted radical prostatectomy. The AR-3D guidance for IFS allows combination of the reduction of positive surgical margins at the level of the index lesion and preservation of neurovascular bundles. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
- Author
-
Rosellini, Matteo, Mollica, Veronica, Marchetti, Andrea, Coluccelli, Sara, Giunchi, Francesca, Tassinari, Elisa, Ricci, Costantino, Fiorentino, Michelangelo, Tallini, Giovanni, De Biase, Dario, and Massari, Francesco
- Subjects
- *
RENAL cell carcinoma , *CHROMOSOMES , *IMMUNE checkpoint inhibitors , *BIOMARKERS , *PROTEIN-tyrosine kinase inhibitors - Abstract
Identifying biomarkers for metastatic renal cell carcinoma (mRCC) is an unmet need in actual immunotherapy era. Available data regarding chromosome 3p genes (i.e., VHL , PBRM1 , SETD2) mutations as potential predictors for therapy response is conflicting. We describe the impact of these mutations on clinical outcomes in mRCC patients treated with immune checkpoint inhibitor (ICI)-doublet or ICI/tyrosine kinase inhibitor (TKI) combinations. We performed a single-center retrospective analysis on mRCC patients treated with first line ICI/ICI or ICI/TKI. A multi-gene panel was used, allowing the amplification of 841 amplicons (54.93 kb, human reference sequence hg19/GRCh37) in the coding sequences of the following genes: ATM, BAP1, KDM5C, MET, MTOR, NF2, PBRM1, PIK3CA, PTEN, SETD2, SMARCB1, TP53, TSC1, TSC2, VHL. 18 patients undergoing ICI/ICI and ICI/TKI who had tumor tissue adequate for molecular analysis were included. Histology was 100% clear cell. IMDC risk was 50% intermediate, 33.4% good, 16.6% poor. First line therapy was 89% ICI/TKI, 11% ICI/ICI. 83.3% pts (n = 15) carried genomic alterations (GA). Most common GA included VHL in 44% (n = 8; 7 pathogenic - PAT and 1 variant of unknown significance - VUS), PBRM1 in 44% (n = 8; 5 PAT and 3 VUS) and SETD2 in 33% (n = 6; 4 PAT and 2 VUS). With the limit of a small sample that did not allow proper statistical analyses, SETD2 -mutated patients had lower median progression free (mPFS) and overall survival (mOS) than non- SETD2 mutated patients. Higher mPFS and mOS were shown with VHL or PBRM1 GA, especially in PBRM1 +VHL mutated pts. Our data shows a possible negative predictive role of SETD2 GA for ICI-based therapy in RCC. Concomitant VHL and PBRM1 GA could act as a predictor for ICI/TKI efficacy. Our hypothesis-generating analysis highlights the need of an integrated evaluation of these genes as promising biomarkers in RCC. Further larger studies are required. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
- Author
-
Mollica, Veronica, Tassinari, Elisa, Santoni, Matteo, Marchese, Paola Valeria, Giunchi, Francesca, Maloberti, Thais, Tateo, Valentina, Ricci, Costantino, Rosellini, Matteo, Marchetti, Andrea, Fiorentino, Michelangelo, Biase, Dario De, and Massari, Francesco
- Subjects
- *
TRANSITIONAL cell carcinoma , *PEMBROLIZUMAB , *CANCER chemotherapy , *GENETIC mutation , *LYMPHATIC metastasis - Abstract
TERT promoter mutation is one of the most common genomic alterations in urothelial carcinoma (UC). Its prognostic role on patients' outcomes is still not clear. We performed a single-center retrospective analysis on patients with advanced UC treated with platinum-based chemotherapy or immunotherapy to assess the presence of somatic TERT −124[C>T] and TERT −146[C>T] mutations and their association with clinicopathologic factors and survival outcomes. Patients were assessed for Overall Survival (OS), Progression-Free Survival (PFS), and Overall Response Rate (ORR). We analyzed 45 UC tumors; 38 of them received first-line chemotherapy and 21 second-line pembrolizumab; 6 patients (13%) harbored −146 C > T TERTp mutation and 25 patients (56%)−124 C > T. The presence of TERT promoter mutations was associated with a higher rate of lower tract UC and a lower rate of synchronous or lymph node metastases. TERT wild-type patients showed higher 12- and 24-months OS-rates in the chemotherapy subgroup and 6-, 12- and 24-months OS rates in the pembrolizumab subgroup. The presence of TERT promoter mutations was also associated with a lower 6 months-PFS rate in patients receiving chemotherapy and in all the three time points in those treated by pembrolizumab. The ORRs of pembrolizumab were 21% and 71% in patients with or without TERT promoter mutations, respectively (p < 0.001). Our analysis suggests that the presence of TERT promoter mutations could negatively affect the outcome of UC patients treated by chemotherapy or pembrolizumab. This hypothesis should be further evaluated in wider cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience.
- Author
-
Dall'Olio, Filippo G., Conci, Nicole, Rossi, Giulio, Fiorentino, Michelangelo, De Giglio, Andrea, Grilli, Giada, Altimari, Annalisa, Gruppioni, Elisa, Filippini, Daria M., Di Federico, Alessandro, Nuvola, Giacomo, and Ardizzoni, Andrea
- Subjects
- *
NON-small-cell lung carcinoma , *ADENOCARCINOMA , *LUNGS , *MOLECULAR diagnosis , *ALGORITHMS - Abstract
• Molecular diagnosis determines treatment for advanced lung adenocarcinoma. • Molecular alterations can be assessed singularly or together within single NGS panel. • Our work compared these strategies in terms of efficacy, cost, tissue saving and time. • NGS offered a less expensive and more reliable model of diagnosis. • NGS also allow to identify concurrent mutations and provides a more rapid result. Molecular diagnosis determines therapeutic strategies for patients with non-small-cell lung cancer – adenocarcinoma (NSCLC-A) but depends on resources availability. We compared a sequential single-gene testing algorithm to next generation sequencing in NSCLC-A to assess differences in terms of effectiveness, costs, tissue consumption and time. We analyzed a retrospective cohort of advanced NSCLC-A patients treated at the Sant'Orsola-Malpighi University Hospital. The sequential testing includes a first analysis of EGFR and KRAS status with further molecular testing physician driven. The available NGS panel detects 35 hotspot mutations,19 amplifications and 23 rearrangements. We included 1758 patients; 1221 characterized with the sequential algorithm between January 2014 to February 2019 and 537 with Next Generation Sequencing (NGS) until January 2020. The prevalence of EGFR, ALK and KRAS alterations was similar between the stepwise and NGS group (16.5% vs 14.3%, 6.3% vs 6.3% and 36% vs 33.5%, respectively). Differently, ROS-1 rearrangements prevalence was higher in stepwise respect to NGS group (4.7% vs 0.7%). Similarly, the stepwise group presented higher prevalence than NGS for MET amplification (11.2% vs 2.2%), MET mutations (9.0% vs 2.4%), HER2 amplification (3.3% vs 1.9%) and mutations (9.8% vs 3.0%), and BRAF mutations (4.5% vs 5.6%). Among the NGS group other mutations were found in 141 patients (26.3%) and the presence of concurrent mutations in 131 (24.4%). The stepwise algorithm presented a relevant dropout rate that increased at each step, with 11.4%, 16.4% and 49.3% respectively for ALK, ROS1 and other analysis. Sequential testing's expenditure was 1375 € per patient, vs 770 € for NGS. Moreover, NGS testing can be performed with just a 25 μm slide respect to an estimated 33.3 μm slide for sequential strategy. NGS offered a less expensive and more reliable model of diagnosis respect to sequential one for patients affected by NSCLC-A. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations.
- Author
-
Trisolini, Rocco, Cancellieri, Alessandra, Livi, Vanina, Annema, Jouke T., Ferrari, Marco, Natali, Filippo, Paioli, Daniela, Conci, Nicole, Altimari, Annalisa, Fiorentino, Michelangelo, and Ardizzoni, Andrea
- Subjects
- *
ADENOCARCINOMA , *NUCLEOTIDE sequencing - Abstract
• NGS of samples obtained from pulmonary adenocarcinoma with psammoma bodies show a high prevalence of mutations, often uncommon and targetable. • Pulmonary adenocarcinoma with psammoma bodies is associated with a reproducible and readily identifiable endobronchial ultrasound pattern ("starry sky sign"). • The identification of the "starry sky sign" during endobronchial ultrasound should lead to an aggressive sampling strategy aimed at obtaining sufficient tissue for a comprehensive molecular profiling. Pulmonary adenocarcinoma with psammoma bodies (PAPBs) is a rare histological variant whose association with a high prevalence of targetable mutations has been suggested by scant literature reports describing small series. We aim to describe the endobronchial ultrasound (EBUS) pattern and the molecular profile by next-generation sequencing of an Italian series of patients with PAPBs. Over a 8-year period (2012–2019), we identified 15 patients with a very uncommon endobronchial ultrasound (EBUS) heterogeneity pattern characterized by the presence of multiple to countless, punctate non-shadowing foci ("starry sky" sign) which were not evident at CT and corresponded to psammoma bodies at pathological examination. The clinical, radiological, pathological and molecular findings of these patients were retrieved and analyzed. Pathological examination of the EBUS-TBNA specimens revealed malignancy (12 pulmonary adenocarcinoma, 2 breast carcinoma, 1 colonic carcinoma) and showed the presence of psammoma bodies in all of the 15 patients with the starry sky sign. Among the 12 patients with pulmonary adenocarcinoma with psammoma bodies, female sex (8/12, 66.7 %) and never-smoking habit (6/12, 50 %) were prevalent. Molecular tumor profiling using the Oncomine™ Focus DNA and RNA fusion panels was successfully performed in 11/12 patients and revealed 10 genetic alterations (BRAF mutation, 4; EGFR mutation, 2; ALK rearrangement, RET rearrangement, PIK3CA mutation, CDK4 amplification 1) in 7 patients (63.6 %). The present series suggests that pulmonary adenocarcinoma with psammoma bodies is associated with a readily identifiable EBUS pattern and with a high prevalence of different, often uncommon and actionable, driver mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
- Author
-
Capizzi, Elisa, Dall'Olio, Filippo Gustavo, Gruppioni, Elisa, Sperandi, Francesca, Altimari, Annalisa, Giunchi, Francesca, Fiorentino, Michelangelo, and Ardizzoni, Andrea
- Subjects
- *
NON-small-cell lung carcinoma , *FLUORESCENCE in situ hybridization , *GENE fusion - Abstract
• NSCLC patients with ROS1 fusions are eligible for first-line therapy with Crizotinib. • Diagnostic FISH criteria were mirrored from ALK , including tumors with 5' deletions. • Response to Crizotinib in patients with ROS1 deletions has never been investigated. • We show that 5' ROS1 deletions are linked with a chance of response to Crizotinib. • Confirmation of ROS1 fusions NGS is beneficial to define the ROS1 fusion partners. Patients harboring rearrangements of the ROS1 gene are eligible for first-line therapy with Crizotinib, which represents the best available treatment option. Diagnostic criteria, based on break-apart fluorescence in situ hybridization, were mirrored from ALK by analogy and include tumors with 5' deletions. However, the probability of response to Crizotinib in patients with 5' deletion in ROS1 is unknown given the rarity of this condition. We hereby describe clinical outcome of 8 NSCLC patients harboring a 5' deletion at FISH treated with Crizotinib Three out of 4 cases whose 5' deletion was confirmed by NGS as a ROS1/EZR fusion displayed an objective response to Crizotinib while a case with ROS1/SDC4 fusion did not. By contrast, among the 4 cases where NGS did not detect ROS1 gene fusions only 2 patients responded to crizotinib therapy with one also harboring a concomitant EML4-ALK rearrangement. 5' ROS1 deletions detected by FISH are associated with a high chance of response to Crizotinib in NSCLC, similarly to canonical ROS1 split-apart FISH rearrangements. However, the confirmation of the ROS1 gene fusion with at least another method, such as NGS, seems beneficial in order to define the ROS1 fusion partner and to avoid possible false positive results. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
28. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
- Author
-
Pernar, Claire H., Ebot, Ericka M., Pettersson, Andreas, Graff, Rebecca E., Giunchi, Francesca, Ahearn, Thomas U., Gonzalez-Feliciano, Amparo G., Markt, Sarah C., Wilson, Kathryn M., Stopsack, Konrad H., Gazeeva, Elizaveta, Lis, Rosina T., Parmigiani, Giovanni, Rimm, Eric B., Finn, Stephen P., Giovannucci, Edward L., Fiorentino, Michelangelo, and Mucci, Lorelei A.
- Subjects
- *
PROSTATE cancer , *PHYSICAL activity , *PROPORTIONAL hazards models , *LONGITUDINAL method , *GENE fusion - Abstract
Growing evidence shows that clinical and molecular subtypes of prostate cancer (PCa) have specific risk factors. Observational studies suggest that physical activity may lower the risk of aggressive PCa. To our knowledge, the association between physical activity and PCa defined by TMPRSS2:ERG has not been evaluated. To prospectively examine the association between physical activity and risk of PCa defined by clinical features and TMPRSS2:ERG. We studied 49 160 men aged 40–75 yr in the Health Professionals Follow-up Study from 1986 to 2012. Data was collected at baseline and every 2 yr with >90% follow-up. Total and vigorous physical activity were measured in metabolic equivalent of task (MET)-h/wk. Advanced PCa was defined as stage T3b, T4, N1, or M1 at diagnosis and lethal PCa as distant metastases or death due to disease over follow-up. Presence of TMPRSS2:ERG was estimated by immunohistochemistry of ERG protein expression. Cox proportional hazards models were used to obtain multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for incidence of subtype-specific PCa. During 26 yr of follow-up, 6411 developed PCa overall and 888 developed lethal disease. There were no significant associations between total physical activity and risk of PCa in the overall cohort. In multivariable-adjusted models, men in the highest quintile of vigorous activity had a significant 30% lower risk of advanced PCa (HR: 0.70, 95% CI: 0.53–0.92) and 25% lower risk of lethal PCa (HR: 0.75, 95% CI: 0.59–0.94) than men in the lowest quintile of vigorous activity. The association was independent of screening history. Vigorous activity was not associated with total PCa in the overall cohort but was inversely associated among highly screened men (top vs bottom quintile, HR: 0.83, 95% CI: 0.70–0.97). Of all cases, 945 were assayed for ERG (48% ERG-positive). Men with higher vigorous activity had a lower risk of ERG-positive PCa (top vs bottom quintile, HR: 0.71, 95% CI: 0.52–0.97). There was no significant association with the risk of ERG-negative disease (p heterogeneity = 0.09). Our study confirms that vigorous physical activity is associated with lower risk of advanced and lethal PCa and provides novel evidence for a lower risk of TMPRSS2:ERG -positive disease. The identification of modifiable lifestyle factors for prevention of clinically important prostate cancer (PCa) is needed. In this report, we compared risk of PCa in men with different levels of physical activity. Men with higher vigorous activity had a lower risk of developing advanced and lethal PCa and PCa with the common TMPRSS2:ERG gene fusion. In this prospective study of physical activity and prostate cancer among 49 160 men, vigorous activity was associated with lower risk of lethal and TMPRSS2:ERG -positive disease. Long-term vigorous activity may be beneficial in prevention of lethal prostate cancer and may involve pathways specific to TMPRSS2:ERG -positive disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
29. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
- Author
-
Capizzi, Elisa, Ricci, Costantino, Giunchi, Francesca, Zagnoni, Stefano, Ceccarelli, Claudio, Gómez, Begoña Urrios Álvarez, Casolari, Laura, Gelsomino, Francesco, Trisolini, Rocco, Fiorentino, Michelangelo, and Ardizzoni, Andrea
- Subjects
- *
IMMUNOHISTOCHEMISTRY , *NON-small-cell lung carcinoma , *IMMUNOTHERAPY , *PEMBROLIZUMAB , *IMMUNOSTAINING - Abstract
Highlights • Currently, only FFPE samples are acceptable for the IHC assessment of PD-L1 in NSCLC. • Cytological smears are the only available material for a subset of patients. • IHC for PD-L1 in cytological smears of NSCLC is feasible using the >50% cut-off. • PD-L1 IHC on cytological smears expands the pool of NSCLC candidate to immunotherapy. Abstract Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the administration as first-line therapy of the anti PD-1 check-point inhibitor Pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Currently, only formalin-fixed paraffin-embedded samples are acceptable for PD-L1 immunostaining with the anti-PD-L1 antibodies 22-C3 and SP263. We investigated retrospectively the accuracy of the anti PD-L1 antibodies 22-C3, 28-28, SP263 in 50 paired histological samples and cytological smears of NSCLC patients. Results The accuracy of the three antibodies for the detection of PD-L1 in histological samples was higher for the antibody SP263 (AUC/ROC = 1) compared to the clones 28-8 (AUC/ROC =,991) and 22-C3 (AUC/ROC =,942). The overall concordance between histological samples and cytological smears using the SP263 clone was moderate (kappa = 0,364). However when the cyto-histological concordance was calculated using just the <50% vs ≥50% cut-off the agreement (kappa = 0.626) was good. The accuracy of the antibody SP263 in cytological smears was good (AUC/ROC =,921). A fluorescent in situ hybridization analysis on 10 histological cases positive for PD-L1 at immunohistochemistry showed amplification of the CD274 gene only in one case. Conclusions Immunocytochemical staining for PD-L1 in diagnostic cytological smears of NSCLC is feasible and applicable at least using the >50% cancer cell cut-off. The three antibodies SP263, 22-C3 and 28-8 are all suitable for the diagnostic detection of PD-L1 on tissue sections with a superiority of the SP263 clone. The implementation of PD-L1 immunocytochemistry on cytological smears will likely expand the pool of NSCLC patients candidate to first-line immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. "Paradoxical" p16 overexpression in cutaneous melanoma: Molecular and immunohistochemical analysis of a rare phenomenon with a focus on cell cycle regulatory molecules.
- Author
-
Ricci, Costantino, Dika, Emi, Corti, Barbara, Lambertini, Martina, Ambrosi, Francesca, Cappilli, Simone, Grillini, Marco, Filippo, Giorgia Di, Franchini, Eugenia, Maloberti, Thais, Fiorentino, Michelangelo, Tallini, Giovanni, and Biase, Dario de
- Subjects
- *
IMMUNOHISTOCHEMISTRY , *GENETIC overexpression , *CELL cycle , *CYCLIN-dependent kinase inhibitors , *GENE expression , *P53 protein , *CELL cycle proteins - Abstract
One of the most relevant genetic alterations in cutaneous melanoma (CM) is the biallelic inactivation/loss-of-heterozygosis (LOH) of cyclin-dependent kinase inhibitor 2 A (CDKN2A), which results in the immunohistochemical loss of p16 frequently found in CM. However, we recently described a rare case of dermal/deep-seated melanoma arising in giant congenital nevus (DDM-GCN) with p16 overexpression combined with p53 loss and tumor protein 53 (TP53) mutation. Herein, we reported a case series of CM with p16 overexpression and analyzed their clinicopathologic features, immunohistochemical expression of the cell cycle regulatory molecules (CCRM: p53, p21, Cyclin D1, Rb), and mutational landscape. We retrospectively tested for p16 all cases of CM diagnosed at our institution between January 1st 2019-April 1st 2022. In CM with p16 overexpression, we reported clinicopathologic features, immunohistochemical results for melanocytic markers and CCRM, and mutational landscape investigated with a next-generation sequencing (NGS) panel. In cases with zonal p16 overexpression, the immunohistochemical assessment for melanocytic markers and CCRM, as well as the NGS analysis have been performed in both components {with and without p16 overexpression [p16(+)c and p16(-)]}. Overexpression of p16 was found in 10/2879 (0.35%) CM [5/10 (50%) diffuse and 5/10 (50%) zonal]. We combined the immunohistochemical results for CCRM and molecular data to classify the cases as follows: a) Group 1 with altered expression of at least one CCRM but no TP53 mutations [3/10 (30%), all with Rb altered/lost]; b) Group 2 with altered expression of at least one CCRM and TP53 mutations [4/10 (40%), all with p53 altered]; c) Group 3 with normal expression of CCRM and no TP53 mutations [3/10 (30%), all with mutations in MAPK pathway genes (NRAS and BRAF)]. In CM with zonal p16 overexpression, the histologic appearance of p16(+)c was heterogeneous, whereas combining CCRM profiles and molecular data the cases could be categorized as follows: a) cases with the same CCRM and molecular profiles in both p16(+)c and p16(-)c; b) cases with p16(+)c showing additional genetic mutations and/or modifications of CCRM expression. p16 overexpression is a rare event, occurring in advanced-stage, clinically- and histologically-heterogeneous CM. These lesions may be classified into three different groups based on CCRM expression and mutational profiles (including TP53 mutation). The analysis of CM with zonal p16 overexpression suggests that, at least in a subset of cases, this phenomenon could represent a sign of "molecular progression" due to the acquisition of additional genetic mutations and/or modifications of the CCRM profile. • p16 overexpression is an exceptionally rare event in CM [10/2879 cases (0.35%)]. • p16 overexpression characterizes advanced-stage, clinically- and histologically-heterogeneous CM. • CM with p16 overexpression may be classified into three groups based on CCRM and molecular results. • In a subgroup of CM with zonal p16 overexpression, p16(+)c could be a sing of molecular progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis.
- Author
-
Melotti, Sofia, Ambrosi, Francesca, Franceschini, Tania, Giunchi, Francesca, Filippo, Giorgia Di, Franchini, Eugenia, Massari, Francesco, Mollica, Veronica, Tateo, Valentina, Bianchi, Federico Mineo, Colecchia, Maurizio, Acosta, Andres Martin, Lobo, João, Fiorentino, Michelangelo, and Ricci, Costantino
- Subjects
- *
GERM cell tumors , *TESTIS tumors , *PROGRAMMED death-ligand 1 , *MANN Whitney U Test - Abstract
In recent years, several studies focused on the process of reprogramming of seminoma (S) cells, which regulates the transition from pure S (P-S) to S component (S-C) of mixed germ cell tumors of the testis (GCTT) and finally to embryonal carcinoma (EC) and other nonseminomatous GCTT (NS-GCTT). The accepted pathogenetic model is driven and regulated by cells (macrophages, B- and T-lymphocytes) and molecules of the tumor microenvironment (TME). Herein, we tested a series of GCTT with double staining (DS) for CD68-PD-L1 to evaluate tumor-associated macrophages (TAMs) expressing programmed death-ligand 1 (PD-L1) [TAMs PD-L1(+)] and clarify if these cells may be involved in establishing the fate of GCTT. We collected 45 GCTT (comprising a total of 62 different components of GCTT). TAMs PD-L1(+) were evaluated with three different scoring systems [ TAMs PD-L1(+)/mm 2 , TAMs PD-L1(+)/mm 2 H-score , TAMs PD-L1(+) % ], and compared using pertinent statistic tests (Student's t-test and Mann-Whitney U test). We found that TAMs PD-L1(+) values were higher in S rather than EC (p = 0.001 , p = 0.015 , p = 0.022) and NS-GCTT (p < 0.001). P-S showed statistically significant differences in TAMs PD-L1(+) values compared to S-C (p < 0.001 , p = 0.006 , p = 0.015), but there were no differences between S-C and EC (p = 0.107 , p = 0.408 , p = 0.800). Finally, we found statistically significant differences also in TAMs PD-L1(+) values between EC and other NS-GCTT (p < 0.001). TAMs PD-L1(+) levels gradually decrease during the reprogramming of S cells {P-S [(high values of TAMs PD-L1(+)] → S-C and EC [(intermediate values of TAMs PD-L1(+)] → other NS-GCTT [(low values of TAMs PD-L1(+)], supporting a complex pathogenetic model where the interactions between tumor cells and TME components [and specifically TAMs PD-L1(+)] play a key role in determining the fate of GCTT. • TAMs PD-L1(+) values were higher in S rather than EC and other NS-GCTT. • P-S showed significant differences in TAMs PD-L1(+) values compared to S-C, but S-C not if compared to the EC. • We found significant differences in TAMs PD-L1(+) values between EC and other NS-GCTT. • TAMs PD-L1(+) levels gradually decrease during the reprogramming of S cells. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen.
- Author
-
Fankhauser, Christian D., Penney, Kathryn L., Gonzalez-Feliciano, Amparo G., Clarke, Noel W., Hermanns, Thomas, Stopsack, Konrad H., Fiorentino, Michelangelo, Loda, Massimo, Mahal, Brandon, Gerke, Travis A., Preston, Mark A., and Mucci, Lorelei A.
- Subjects
- *
PROSTATE-specific antigen , *PROSTATE cancer , *CASTRATION-resistant prostate cancer , *MEDICAL personnel , *CANCER , *GLEASON grading system - Published
- 2020
- Full Text
- View/download PDF
33. Unusual asymptomatic presentation of bladder cancer metastatic to the penis.
- Author
-
Giunchi, Francesca, Vasuri, Francesco, Valerio, Vagnoni, Montagnani, Ilaria, Nelli, Federico, Fiorentino, Michelangelo, and Raspollini, Maria Rosaria
- Subjects
- *
BLADDER cancer , *METASTASIS , *PENIS , *GENITAL warts , *CARCINOMA - Abstract
Penile metastasis is an extremely rare event and mainly originate from primary pelvic tumor sites such us urinary bladder, gastro-intestinal tract and prostate and more rarely from respiratory system, bone tumors and melanoma. Here we describe the unusual presentation of two bladder urothelial cancer metastatic to the penis with no relevant clinical symptoms. Namely, a 69 years-old man with a warthy lesions of the foreskin and the glans misunderstood for a condylomata that at histological and immunohistochemical analysis showed a bladder urothelial carcinoma; and a 71 years-old man with reddish skin lesion of the glans, a previous history of bladder and urethral carcinoma and histological pagetoid spread of urothelial cancer to the glans. Recurrent bladder urothelial carcinoma is usually a visceral disease that rarely presents as a superficial asymptomatic skin lesion. The two reported cases were asymptomatic superficial penis metastases with a relatively slow growth and a fairy good prognosis after conservative surgical approach. Accurate clinical examination of the penis is mandatory for males with history of bladder cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
34. H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma.
- Author
-
Ricci, Costantino, Ambrosi, Francesca, Franceschini, Tania, Giunchi, Francesca, Maracci, Maria Eugenia, Sirolli, Maria, Orsatti, Agnese, Chiarucci, Federico, Franchini, Eugenia, Borsato, Matteo, Massari, Francesco, Mollica, Veronica, Bianchi, Federico Mineo, Colecchia, Maurizio, Acosta, Andres Martin, and Fiorentino, Michelangelo
- Subjects
- *
SEMINOMA , *GERM cell tumors , *TESTIS tumors , *HEMATOXYLIN & eosin staining , *CARCINOMA - Abstract
Lymphovascular invasion (LVI) is a relevant prognostic factor in germ cell tumors of the testis (GCTT), and it is included in the pT stage. However, its detection on hematoxylin and eosin (H&E) slides is very challenging, and previous studies reported fair to moderate inter-observer agreement among dedicated uropathologists. In the present study, we tested H&E and a recently developed in-house double staining for OCT4/CD34 to detect LVI in GCTT. Nine authors [5 non-uropathologists and 4 uropathologists] independently evaluated 34 consecutive and retrospectively enrolled cases of GCTT. We assessed the inter-observer agreement (Fleis s's Kappa) with both H&E and OCT4/CD34. Besides, we compared the consensus diagnosis on both H&E and OCT4/CD34-stained sections with the original diagnosis to evaluate the pT re-staging (McNemar test) and identify the sources of disagreement. The inter-observer agreement among uropathologists plus non-uropathologists was fair with both H&E (KF=0.398; p < 0.001) and OCT4/CD34 (KF=0.312; p < 0.001). OCT4/CD34 (KF=0.290; p < 0.001) slightly reduces the inter-observer agreement compared to H&E (KF=0.321; p < 0.001) for non-uropathologists; in contrast, OCT4/CD34 (KF=0.293; p < 0.001) significantly reduces the inter-observer agreement compared to H&E (KF=0.529; p < 0.001) for uropathologists, changing it from moderate to fair. Consensus diagnosis with H&E modified the LVI status of the original diagnosis in 8/34 (23.5 %) cases (p: 0.070), with pT re-staging in 2/34 (5.9 %) cases (p: 0.500). Consensus diagnosis with OCT4/CD34 modified the LVI status of the original diagnosis in 8/34 (23.5 %) cases (p: 0.289), with pT re-staging in 3/34 (8.8 %) cases (p: 0.250). The consensus diagnosis with OCT4/CD34 modified the consensus diagnosis with H&E in 8/34 (23.5 %) cases (p: 0.727), and these findings resulted in pT-restaging in 3/34 (8.8 %) cases (p: 0.500). The sources of disagreement among uropathologists were: H&E [artefactual clefts misinterpreted as LVI in 4/6 (66.7 %) cases and true foci of LVI misinterpreted as clusters of histiocytes within the vessels in 2/6 (33.3 %) cases], OCT4/CD34 [artefactual clefts misinterpreted as LVI in 2/8 (25 %) cases, true LVI misinterpreted as artefactual clefts in 2/8 (25 %) cases or floaters in 4/8 (50 %) cases]. OCT4/CD34 does not improve the inter-observer agreement for the assessment of LVI in OCT4(+) GCTT. Consensus diagnosis with H&E modifies the LVI status in a significant number of cases, resulting in changes of the pT stage in a relatively small subgroup. Consensus diagnosis with OCT4/CD34 provides little additional benefit since it cannot exclude mimickers of LVI such as floaters and artefactual clefts. These results argue against the adoption of this diagnostic tool for the routine assessment of OCT4(+) GCTT. • The best values of IrOA are obtained by UPs on H&E slides, with OCT4/CD34 not improving the IrOA in all groups. • CD modify the LVI in a significant number of cases, but the effect on the pT re-staging is less relevant. • The main sources of disagreement among UPs are artefactual clefts and histiocytes within the vessels on H&E slides. • The main sources of disagreement among UPs are artefactual clefts and floaters on OCT4/CD34 slides. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1...but choriocarcinoma?
- Author
-
Ricci, Costantino, Ambrosi, Francesca, Franceschini, Tania, Giunchi, Francesca, Franchini, Eugenia, Massari, Francesco, Mollica, Veronica, Bianchi, Federico Mineo, Colecchia, Maurizio, Acosta, Andres Martin, and Fiorentino, Michelangelo
- Subjects
- *
YOLK sac , *CHORIOCARCINOMA , *TESTIS tumors , *GERM cell tumors , *GENITALIA - Abstract
The recently described SWI/SNF complex-deficient sinonasal carcinoma (SMARCB1 & SMARCA4) may exhibit a yolk sac-like morphology. Tumors with similar features (yolk sac-like histology combined with the immunohistochemical loss of SMARCB1/INI1 and/or SMARCA4/BRG1) have also been described in other sites, such as the female genital tract. In this study, we immunohistochemically assessed SMARCB1/INI1 and SMARCA4/BRG1 expression to evaluate if these proteins could be involved in the pathogenesis of testicular yolk sac tumors of postpubertal type (YSTpt). Specifically, we analyzed a retrospective case series comprising pure YSTpt and mixed germ cell tumors of the testis (GCTT) with YSTpt components. In the present study, no testicular YSTpt showed loss of SMARCB1/INI1 (0/24, 0%) or SMARCA4/BRG1 (0/24, 0%). However, testicular choriocarcinoma (CHC) and isolated syncytiotrophoblast cells (iSTCs) demonstrated abnormal staining patterns for SMARCA4/BRG1 [CHC: 4/4 (100%); iSTCs: 12/12 (100%), respectively], including focal or diffuse loss of expression in a subset of cases. The results of our study suggest that functional loss of SMARCA4/BRG1 represents a recurrent event that may be relevant for the pathogenesis of a subset of testicular CHC. • Testicular YSTpt does not show immunohistochemical loss of SMARCA4/BRG1 and SMARCB1/INI1. • SWI/SNF complex is most likely not involved or has a limited role in the pathogenesis of testicular YSTpt. • Testicular CHC exhibited significant alterations of SMARCA4/BRG1 stain, more pronounced in the syncytiotrophoblasts. • A subset of testicular CHC may harbor molecular alterations in the components of the SWI/SNF complex. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Apoptosis in alcoholic hepatitis
- Author
-
Farinati, Fabio, Cardin, Romilda, and Fiorentino, Michelangelo
- Published
- 2002
- Full Text
- View/download PDF
37. SOX2 and PRAME in the "reprogramming" of seminoma cells.
- Author
-
Orsatti, Agnese, Sirolli, Maria, Ambrosi, Francesca, Franceschini, Tania, Giunchi, Francesca, Franchini, Eugenia, Grillini, Marco, Massari, Francesco, Mollica, Veronica, Bianchi, Federico Mineo, Colecchia, Maurizio, Fiorentino, Michelangelo, and Ricci, Costantino
- Subjects
- *
SEMINOMA , *GERM cell tumors , *MANN Whitney U Test , *TESTIS tumors , *LEYDIG cells - Abstract
In recent years, several studies investigated the complex process called "reprogramming" of seminoma (S) cells. The accepted pathogenetic model is a complex network including SOX2, SOX17, OCT3/4 and PRAME, which modulates the epigenetic transcription of numerous downstream genes and drives a divergent gene expression profile resulting in the transition from pure S (P-S) to S component (S-C) of mixed germ cell tumors of the testis (M-GCTT), and finally to embryonal carcinoma (EC). Herein, we tested a large cohort of GCTT with SOX2 and PRAME to evaluate their expression in the evolutionary steps of GCTT and verify if the modulation in the expression of these two molecules could be relevant for the fate of GCTT. We tested 43, 19 and 17 consecutive and retrospectively enrolled cases of GCTT, germ cell neoplasia in situ (GCNIS) and uninvolved background testes (UBT), respectively. SOX2 and PRAME expressions have been evaluated with H-score and compared by adopting the appropriate statistic tests (Student's t-test and Mann-Whitney U test). We found that SOX2 was more expressed by nonseminomatous-GCTT (NS-GCTT) (p < 0.001) and EC (p < 0.001) rather than S; by contrast, PRAME showed an opposite expression profile being expressed by S but not by NS-GCTT (p < 0.001) and EC (p < 0.001). S-C showed different expressions of SOX2 and PRAME compared to both P-S (p = 0.002 and <0.001 , respectively) and EC (p < 0.001 and 0.042 , respectively), with intermediate values between these latter two categories. GCNIS and UBT showed no expression of SOX2 (scattered positive Leydig cells) but high H-score levels of PRAME. SOX2 and PRAME are differentially expressed and specularly modulated during the "reprogramming" of S cells [P-S (high levels of PRAME, no expression/low levels of SOX2) → S-C (intermediate levels of PRAME, intermediate levels of SOX2) → EC (no expression/low levels of PRAME, high levels of SOX2)], therefore supporting a complex pathogenetic model where the interactions between these two molecules are crucial in determining the fate of GCTT. • SOX2 and PRAME are differentially expressed and specularly modulated during the "reprogramming" of S cells. • SOX2 and PRAME are implicated in the pathogenetic model determining the fate of GCTT. • SOX2 expression is observed in iSTCs. • Re-expression of SOX2 could be observed in the epithelial components of T and YST with glandular/alveolar pattern. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
- Author
-
Marchese, Paola Valeria, Mollica, Veronica, De Biase, Dario, Giunchi, Francesca, Tassinari, Elisa, Marchetti, Andrea, Rosellini, Matteo, Nuvola, Giacomo, Maloberti, Thais, Fiorentino, Michelangelo, and Massari, Francesco
- Subjects
- *
TRANSITIONAL cell carcinoma , *IMMUNE checkpoint inhibitors , *BRAF genes , *GENETIC mutation , *RITUXIMAB , *PROGRESSION-free survival , *SURVIVAL rate - Abstract
The therapeutic scenario of urothelial carcinoma is constantly expanding with the widening of the knowledge on molecular characteristics, thus claiming for the need of prognostic and predictive factors to guide treatment strategy. TERT promoter mutation is one of the most frequent genomic alterations in urothelial carcinoma and could present several implications, from diagnostic to prognostic or potentially even predictive. We performed a single-center retrospective analysis on patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor as second line of therapy to assess the status of the TERT promoter and the potential implication of its mutation on survival outcomes. We analyzed tissue samples from 11 patients with a next-generation sequencing multi-gene panel. The most frequently altered genes were TP53 (54.5%, n = 6) and TERT promoter (36.3%, n = 4). Other mutations found were BRAF, SMAD4, PIK3CA / PDGRFA. The only type of detected TERT promoter mutation was the c 0.124 C>T (n = 4/4, 100%). Of the 4 TERT mutated patients, 2 presented a co-mutation of TP53. Patients with TERT promoter mutation treated with immunotherapy presented a low median overall survival (16.5 months) and progression-free survival (3.8 months). Our hypothesis-generating analysis suggests that the presence of TERT promoter mutation could have a negative prognostic value and should be further evaluated in wider cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?
- Author
-
Di Sciascio, Luisa, Ambrosi, Francesca, Franceschini, Tania, Giunchi, Francesca, Franchini, Eugenia, Massari, Francesco, Bianchi, Federico Mineo, Colecchia, Maurizio, Fiorentino, Michelangelo, and Ricci, Costantino
- Subjects
- *
CARCINOMA in situ , *MANN Whitney U Test , *HEMATOXYLIN & eosin staining , *PROGNOSIS - Abstract
The differential diagnosis between flat urothelial lesions [reactive urothelial atypia (RUA), atypia of unknown significance (AUS), urothelial dysplasia (UD) and carcinoma in situ (CIS)] has relevant prognostic and therapeutic implications. This crucial distinction could be very challenging but it is currently performed on hematoxylin and eosin (H&E) slides, with a great amount of partially discordant and/or not conclusive findings of the potential adjunctive role of immunohistochemistry. Herein, we tested double staining (DS) for p53/CK20 to verify if p53(+) cells, CK20(+) cells and double-positive cells (DPCs) are differentially expressed among these lesions and if p53/CK20 could be a useful tool in this diagnostic setting. We tested 50, 9, 36 and 29 consecutive and retrospectively enrolled cases of RUA, AUS, UD and CIS, respectively. p53(+) cells, CK20(+) cells and DPCs were evaluated and compared by adopting the appropriate statistic tests (Mann-Whitney U and Kruskal-Wallis tests). We found that p53(+) cells (p = 0.000), CK20(+) cells (p = 0.000) and DPCs (p = 0.000) showed statistically significant differences among the different flat urothelial lesions. Besides, when dichotomized, both CIS and RUA are easily differentiable from their histological mimickers adopting all these markers; by contrast, AUS and UD did not reach statistically significant differences able to differentiate them from each other [p53(+) cells, p = 0.123 ; CK20(+) cells, p = 0.567 ; DPCs, p = 0.409 ], except if compared to CIS [AUS VS CIS: p53(+) cells, p = 0.013 ; CK20(+) cells, p = 0.000 ; DPCs, p = 0.000 ; UD vs CIS: p53(+) cells, p = 0.000 ; CK20(+) cells, p = 0.000 ; DPCs, p = 0.000 ]. p53(+) cells, CK20(+) cells and DPCs are differently expressed by flat urothelial lesions and p53/CK20 could be a time- and money-saving tool for the appropriate management of these lesions if applied to a routine scenario. • p53(+) cells, CK20(+) cells and DPCs show different levels of expression among the different flat urothelial lesions. • AUS and UD are not differentiable from an immunohistochemical point of view and remain difficult categories to identify. • DPCs shows the best discrimination power among the different histological classes. • p53/CK20 could be a useful diagnostic tool for the appropriate classification of these lesions in a routine scenario. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples.
- Author
-
Ambrosi, Francesca, Giunchi, Francesca, Capizzi, Elisa, Cancellieri, Alessandra, Trisolini, Rocco, Ardizzoni, Andrea, Fiorentino, Michelangelo, and Ricci, Costantino
- Subjects
- *
PROGRAMMED death-ligand 1 , *PATIENT selection , *NON-small-cell lung carcinoma , *PROGRAMMED cell death 1 receptors - Abstract
The PD-L1 assessment is mandatory for the selection of patients affected by advanced non-small-cell lung cancer (NSCLC) who can benefit from the PD-1/PD-L1 checkpoint inhibitors therapy. Previous studies tested PD-L1 on cytological smears to evaluate this sample as an alternative to formalin-fixed paraffin-embedded (FFPE) ones, but several critical issues needed to be clarified. We evaluated the cyto-histological agreement (CHA) and the PD-L1 interobserver agreement (IrOA) among three different pathologists (Path1, Path2, Path3) on 160 paired cytological smears and histological samples of advanced NSCLC. With the cut-off of < 50%/≥ 50%, CHA resulted good for Path1 (Cohen's k : 0.702) and Path3 (Cohen's k : 0.731), moderate for Path2 (Cohen's k : 0.576) adopting the same cut-off, the IrOA was moderate (ICC 0.72 [95% CI: 0.63–0.78]) for smears and good for histological samples (ICC 0.85 [95% CI: 0.80–0.85]). With a cut-off system of < 50%/≥ 50%, PD-L1 assessment shows moderate to good CHA and exhibited moderate IrOA on smears and good IrOA on FFPE. As result, PD-L1 assessment should be improved on cytological smears as well as could be a suitable alternative for patients without FFPE samples and not eligible for pembrolizumab, adopting a cut-off of < 50%/≥ 50%; presumably, an appropriate pathologist training could further improve the reproducibility. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Hematoxylin and eosin or double stain for CD34/SOX10: Which is better for the detection of lymphovascular invasion in cutaneous melanoma?
- Author
-
Ricci, Costantino, Dika, Emi, Lambertini, Martina, Ambrosi, Francesca, Grillini, Marco, Chillotti, Stefano, Corradini, Angelo Gianluca, Veronesi, Giulia, Fiorentino, Michelangelo, and Corti, Barbara
- Subjects
- *
HEMATOXYLIN & eosin staining , *BREAST cancer prognosis , *LYMPHATIC metastasis , *INTRACLASS correlation , *MELANOMA , *GAUSSIAN distribution , *CD30 antigen - Abstract
Lymphovascular invasion (LVI) is considered an unfavorable prognostic factor in cutaneous melanoma (CM). However, its detection by hematoxylin and eosin (H&E) is challenging, with discordant data about its association with clinical-pathological features and no previous studies investigating the inter- (IrOA) and intra-observer (IaOA) agreement. Herein, we tested H&E and double staining (DS) for CD34/SOX10 to detect the LVI in a cohort of 92 CMs, evaluating the IrOA, the IaOA, and the association with the other clinical-pathological features. Five authors independently evaluated 92 consecutive and retrospectively enrolled cases of CMs. We assessed the IrOA (Fleiss's Kappa/FK and intraclass correlation coefficient/ICC) and the IaOA (Cohen's Kappa/CK) with both H&E and CD34/SOX10. Furthermore, we compared the LVI assessment with the two stains and analyzed the association with other clinical-pathological features [χ2 tests for dichotomous and categorical data; Student t -test (normal distribution) and Mann-Whitney U -test (non-normal distribution) for continuous data]. The IrOA was almost identical with H&E (FK=0.446; ICC=0.805) and CD34/SOX10 (FK=0.454; ICC=0.810); by contrast, the IaOA was higher with H&E for one pathologist (CK: 0.809) and with CD34/SOX10 for the other one (CK: 0.563). Applying previously defined criteria, LVI was detected in 10 (9.2%) and 11 (10.1%) cases with H&E and CD34/SOX10, respectively (p = 1.000). Both H&E and CD34/SOX10 were significantly associated with vertical growth phase (H&E, p: 0.014 ; CD34/SOX10, p: 0.010), mitosis ≥ 1/mm2 (H&E, p: 0.000 ; CD34/SOX10, p: 0.004), pT (H&E, p: 0.000 ; CD34/SOX10, p: 0.001), Breslow thickness (H&E, p: 0.000 ; CD34/SOX10, p: 0.001), and lymph node and/or distant metastasis (H&E, p: 0.005 ; CD34/SOX10, p: 0.000); only H&E was associated with ulceration (p: 0.002) and distant metastasis (p: 0.000), conversely, only CD34/SOX10 was associated with lymph node metastasis (p: 0.003). CD34/SOX10 does not improve the IrOA and the IaOA of the LVI assessment in CM; furthermore, H&E and CD34/SOX10 show a similar profile of association with the other unfavorable clinical-pathological features of CM. As result, CD34/SOX10 could be a redundant diagnostic tool if applied for the prognostic characterization of not-selected CM in a routine diagnostic scenario. • CD34/SOX10 does not increase the inter-observer agreement between dermatopathologists (DPs) and non-DPs. • CD34/SOX10 provides peculiar and unexpected results regarding the intra-observer agreement between DPs and non-DPs. • Adopting strictly defined criteria and with consensus review, CD34/SOX10 does not increase LVI detection. • H&E and CD34/SOX10 were associated with unfavorable features (growth phase, mitoses, pT, Breslow and metastases). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma.
- Author
-
Ricci, Costantino, Dika, Emi, Lambertini, Martina, Ambrosi, Francesca, Chiarucci, Federico, Chillotti, Stefano, Fiorentino, Michelangelo, Fabbri, Erich, Tassone, Daniela, Veronesi, Giulia, Tartari, Federico, and Corti, Barbara
- Subjects
- *
SENTINEL lymph node biopsy , *MELANOMA , *COVID-19 , *NEVUS - Abstract
The diagnosis of nodal nevi (NN) is challenging as they mimic melanoma metastases (MM), with a detection rate mostly ranging between 1% and 11% in sentinel lymph node biopsy (SLNB). Herein, we assessed the incidence of NN and the association with the clinical-pathological features of primary melanoma, adopting the updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for SLNB. All cases of paired melanoma and SLNB were retrospectively evaluated (April 2019-May 2020). Appropriate statistical tests were adopted, with significant variables included in the logistic regression model. 81 patients and a total of 186 lymph nodes (LNs) were included. Eleven patients had only NN and 4 had both NN and MM (18.5%); 29 LNs (15.6%) showed at least one NN and 12 (6.5%) showed more than one NN (a total amount of 43 NN was detected). All NN and none MM stained for p16. NN were associated with age < 60 years (p: 0.042), no ulceration (p: 0.025) and nevus-associated melanoma (NAM) (p: 0.018), with this latter being the only predictor at the logistic regression model (p: 0.022). The updated EORTC protocol shows a high number of NN and highlights a strong association with NAM. • The diagnosis of nodal nevi is challenging as they mimic melanoma metastases, especially on sentinel lymph node biopsy. • The number of NN in SLNB of melanoma with the updated EORTC protocol is higher than what shown by previous protocols. • This increase does not implicate an over-diagnosis of MM if the EORTC protocol is properly performed. • NN are associated with nevus-associated melanoma, which differs from de-novo melanoma not only for clinical-pathological features. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
43. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy
- Author
-
Nguyen, Paul L., Lin, Douglas I., Lei, Junyi, Fiorentino, Michelangelo, Mueller, Elke, Weinstein, Michael H., Pagano, Michele, and Loda, Massimo
- Subjects
- *
PROSTATECTOMY , *GENE expression , *PROTEIN kinases , *PROSTATE cancer prognosis , *IMMUNOHISTOCHEMISTRY , *CLINICAL biochemistry , *BIOMARKERS - Abstract
Abstract: Background: In several human cancers, overexpression of Skp2 (S-phase kinase associated protein 2), which targets p27 for degradation, portends a poorer prognosis. We examined whether Skp2 overexpression is associated with recurrence following radical prostatectomy (RP) for prostate cancer. Methods: Immunohistochemical staining for Skp2, p27, and MIB-1 was performed on 109 men with node-negative prostate cancer surgically managed from 1985–1996. Associations between the stains were tested and Cox regression was used to determine the association between Skp2 expression and time to biochemical recurrence following RP. Results: The 12 tumors (11%) with Skp2 overexpression all had correspondingly low p27 expression (P = 0.006), and a similar inverse Skp2/p27 relationship was seen in vitro in LNCap cells. Skp2 overexpression in tissue was associated with higher Gleason score (P = 0.002), more advanced pathological stage (P = 0.01), and higher MIB-1 index (P = 0.03), but a more favorable PSA profile (P = 0.04). Five men received a TURP. Among 104 who received RP, median follow-up was 67 months (range: 0.2–218). After adjusting for PSA, pathologic stage, and Gleason score, Skp2 overexpression remained significantly associated with a shorter time to biochemical recurrence (adjusted hazard ratio 4.8 (95% C.I. 1.6–14, P = 0.004)). The median time to recurrence with high vs. low Skp2 was 4 vs. 54 months. Conclusions: Skp2 overexpression was seen in a significant minority of surgically-managed men and was independently associated with a higher risk of recurrence, raising the possibility that Skp2 could be useful as a prognostic biomarker and as a potential molecular target for novel systemic agents in prostate cancer. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
44. A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34.
- Author
-
Ricci, Costantino, Franceschini, Tania, Giunchi, Francesca, Borsato, Matteo, Mollica, Veronica, Massari, Francesco, and Fiorentino, Michelangelo
- Subjects
- *
GERM cell tumors , *TESTIS tumors , *PROGNOSIS - Abstract
Lymphovascular invasion (LVI) is a relevant prognostic factor in germ cell tumors of the testis (GCTT) and it has been included in the AJCC staging system. Nevertheless, its histological assessment is challenging, with low/moderate interobserver agreement also among expert uropathologists. Few studies focused on the potential role of immunohistochemistry to solve this critical issue; as result, in current guidelines there is no indication for additional staining to detect this histological feature. In the present study, we investigated the detection of LVI invasion in a small cohort of GCTT with double staining for OCT4/CD34. Although our results need to be validated in larger case series with follow-up data, they suggest as OCT4/CD34 could be a useful tool for the histological assessment of these tumors, helping to identify some histological mimickers of LVI and modifying the pT/stage in a significant percentage of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial.
- Author
-
Schiavina, Riccardo, Droghetti, Matteo, Novara, Giacomo, Bianchi, Lorenzo, Gaudiano, Caterina, Panebianco, Valeria, Borghesi, Marco, Piazza, Pietro, Mineo Bianchi, Federico, Guerra, Marco, Corcioni, Beniamino, Fiorentino, Michelangelo, Giunchi, Francesca, Verze, Paolo, Pultrone, Cristian, Golfieri, Rita, Porreca, Angelo, Mirone, Vincenzo, and Brunocilla, Eugenio
- Subjects
- *
PROSTATE cancer , *MAGNETIC resonance imaging , *PROSTATE cancer patients , *ENDORECTAL ultrasonography , *SPINAL fusion , *PROSTATE tumors treatment , *EVALUATION of medical care , *RESEARCH , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *RISK assessment , *COMPARATIVE studies , *RANDOMIZED controlled trials , *PROSTATE tumors , *LONGITUDINAL method - Abstract
Background: We aim to evaluate the impact of multiparametric magnetic resonance imaging and fusion-target biopsy for early reclassification of patients with low-risk Prostate Cancer in a randomized trial.Materials and Methods: Between 2015 and 2018, patients diagnosed with Prostate Cancer after random biopsy fulfilling PRIAS criteria were enrolled and centrally randomized (1:1 ratio) to study group or control group. Patients randomized to study group underwent multiparametric magnetic resonance imaging at 3 months from enrollment: patients with positive findings (PIRADS-v2>2) underwent fusion-target biopsy; patients with negative multiparametric magnetic resonance imaging or confirmed ISUP - Grade Group 1 at fusion-target biopsy were managed according to PRIAS schedule and 12-core random biopsy was performed at 12 months. Patients in control group underwent PRIAS protocol, including a confirmatory 12-core random biopsy at 12 months. Primary endpoint was a reduction of reclassification rate at 12-month random biopsy in study group at least 20% less than controls. Reclassification was defined as biopsy ISUP Grade Group 1 in >2 biopsy cores or disease upgrading.Results: A total of 124 patients were randomized to study group (n = 62) or control group (n = 62). Around 21 of 62 patients (34%) in study group had a positive multiparametric magnetic resonance imaging, and underwent fusion-target biopsy, with 11 (17.7%) reclassifications. Considering the intention-to-treat population, reclassification rate at 12-month random biopsy was 6.5% for study group and 29% for control group, respectively (P < 0.001).Conclusions: The early employment of multiparametric magnetic resonance imaging for active surveillance patients enrolled after random biopsy consents to significantly reduce reclassifications at 12-month random biopsy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
46. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.
- Author
-
Rizzo, Alessandro, Mollica, Veronica, Rosellini, Matteo, Marchetti, Andrea, Ricci, Angela Dalia, Fiorentino, Michelangelo, Battelli, Nicola, Santoni, Matteo, and Massari, Francesco
- Subjects
- *
META-analysis , *CASTRATION-resistant prostate cancer , *PROSTATE cancer patients , *ANDROGEN receptors , *LYMPHATIC metastasis , *CLINICAL trials , *VISCERAL pain - Abstract
The Androgen Receptor Splice Variant 7 (AR-V7) has been associated with poor clinical outcomes in patients with castration-resistant prostate cancer (CRPC). Herein, we performed a meta-analysis aimed at systematically exploring the association between metastatic sites and AR-V7 expression in CRPC patients across prospective clinical trials. We retrieved all the relevant prospective clinical trials through PubMed/Medline, Cochrane library, and EMBASE; additionally, proceedings of the main international oncological meetings were also searched for relevant abstracts. Outcomes of interest included metastatic sites (lymph node metastases, any site metastases, visceral metastases, and bone metastases) in AR-V7 positive and AR-V7 negative CRPC patients. Odds Ratios (ORs) and 95 % confidence intervals (CI) were calculated. Overall, 14 eligible prospective studies involving a total of 1944 CRPC patients (AR-V7 positive: 467; AR-V7 negative: 1477) were included in the analysis. According to our results, no differences between AR-V7 positive and AR-V7 negative CRPC patients were observed in terms of lymph node (OR 1.01; 95 % CI 0.49–2.09) and visceral metastases (OR 1.23; 95 % CI 0.89–1.71). Conversely, AR-V7 positive CRPC patients presented higher rate of any site metastases (OR 2.22; 95 % CI 1.58–3.12) and bone metastases (OR 2.03; 95 % CI 1.42–2.9) compared to AR-V7 negative subjects. The results of this meta-analysis, the first in literature to be specifically focused on this topic so far, suggest that AR-V7 positivity may be associated with any site metastases and bone metastases; conversely, no association has been highlighted between AR-V7 expression and lymph node or visceral metastases. Although this meta-analysis should be interpreted with caution due to some limitations, our findings confirm that AR-V7 status could designate a unique and peculiar subtype of PC. Further studies aimed at improving and standardizing AR-V7 detection in clinical trials on CRPC patients are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience.
- Author
-
Rizzo, Alessandro, Mollica, Veronica, Giunchi, Francesca, Dall'Olio, Filippo Gustavo, Rosellini, Matteo, Marchetti, Andrea, Franceschini, Tania, Schiavina, Riccardo, Brunocilla, Eugenio, Fiorentino, Michelangelo, Ardizzoni, Andrea, and Massari, Francesco
- Subjects
- *
TRANSITIONAL cell carcinoma , *PROGNOSIS , *TREATMENT effectiveness , *IN situ hybridization , *PEMETREXED , *STATISTICAL significance , *GENE amplification - Abstract
In recent years, HER2 amplification has been evaluated as a potential prognostic biomarker and therapeutic target in urothelial carcinoma (UC). In this retrospective study, we aimed at exploring the prognostic role of HER2 amplification in UC, measured by chromogenic in situ hybridization (CISH). We retrospectively evaluated the presence of HER2 amplification by using CISH in 31 UC patients followed at a single institution between 2018 and 2020. The primary objective was to assess the frequency of HER2 amplification and to compare clinical outcomes of HER2-amplified patients with non-amplified UCs. HER2 amplification was identified in 4 out of 31 patients (12.9 %). After a median follow-up of 28.1 months (95 % Confidence Intervals [CI] 11.2–45.1), median overall survival (OS) in the whole population was 10.9 months (95 % CI 3.5–22.1). Despite not reaching statistical significance, median OS was shorter in HER2-amplified patients (6.8 months, 95 % CI 3.9–9.7) compared to HER2-negative UCs (15.4 months, 95 % CI 7.5–23.3) (p = 0.45). Although limited by the small sample size, the results of our study suggest that HER2 amplifications by CISH could represent a prognostic factor for shorter survival in UC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing.
- Author
-
Mollica, Veronica, Franceschini, Tania, Gruppioni, Elisa, Rizzo, Alessandro, Ricci, Costantino, Schiavina, Riccardo, Brunocilla, Eugenio, Ardizzoni, Andrea, Fiorentino, Michelangelo, Giunchi, Francesca, and Massari, Francesco
- Subjects
- *
RENAL cell carcinoma , *SPECTRUM analysis , *PROGNOSIS , *SEQUENCE analysis , *GENES - Abstract
Chromophobe renal cell carcinoma (ChRCC) is a rare subtype of non-clear cell renal cell carcinoma. Due to its rarity, its molecular characterization as well as therapeutic targets are still not fully understood. We performed a next-generation sequencing analysis using the platform Ion PGM System on 20 retrospectively collected ChRCC cases with the aim of identify molecular biomarkers with potential prognostic value or that could have therapeutic implications. We identified mutation on TP53, SMARCB1, RB1 and JAK3. The most frequently altered gene was TP53 (6/20, 30 % of cases). SMARCB1 mutation was found in 3 (15 %) patients and in all cases the mutational variant was p.T72 K, with known pathogenenic meaning. One (5%) patient presented a pathogenetic mutation of RB1. JAK3 was mutated in 1 (5%) patient and this mutation resulted to have uncertain pathogenetic significance. ChRCC is a rare disease still not fully molecularly characterized. Next-generation sequencing analysis could be useful to identify potential mutation with prognostic value or that could be potential therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer.
- Author
-
Franceschini, Tania, Capizzi, Elisa, Massari, Francesco, Schiavina, Riccardo, Fiorentino, Michelangelo, and Giunchi, Francesca
- Subjects
- *
GENE amplification , *BLADDER cancer , *HER2 gene , *HER2 protein , *TRANSITIONAL cell carcinoma , *IN situ hybridization - Abstract
HER2 is a potential target of therapy in urothelial cancer (UC). Pathological case stratification according to HER2 gene amplification or HER2 protein overexpression was critical for patients' selection in previous unsuccessful clinical trial with HER2 targeting agents. We evaluated the HER2 overexpression by immunohistochemistry (IHC) together with the amplification of the HER2 gene with chromogenic(CISH) and fluorescent (FISH) in situ hybridization in a cohort of 61 patients covering the whole spectrum of bladder UC variants, using a tissue microarray (TMA) approach. IHC was available in all the 61 cases while ISH in 37 and FISH in 42. At IHC, 2/61 cases (3%) were scored 3+; 2 (3%) scored 2+; 2 (3%) scored 1+; the remaining 55 (91%) scored 0. At CISH analysis 10/37 cases (27%) were amplified, 6 cases with HER2 amplification showed positive HER2 IHC (3+, 2+, 1+). Seven cases with IHC score 0 were amplified at CISH. FISH analysis revealed an amplification in 5/42 cases (12%). The total number of HER2 amplified cases was different between chromogenic and fluorescent ISH with 5 cases amplified using FISH compared to 10 with CISH. In clinical trials with HER2 targeting agents the candidate patients should be investigated not only by IHC but also by ISH, independently of the IHC results. Since also usual type UC can overexpress HER2 we recommend to extend the patients' selection to all the histotypes of bladder cancer other than the micropapillary type. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
50. Pd-ligand 1 is expressed in inflammatory cells but not in neoplastic cells in hepatocellular carcinoma: An immunohistochemical study.
- Author
-
Vasuri, Francesco, Nerpiti, Azzurra, Zagnoni, Stefano, Ravaioli, Matteo, D'Errico, Antonia, and Fiorentino, Michelangelo
- Subjects
- *
HEPATOCELLULAR carcinoma , *BEHAVIORAL assessment , *HISTOCHEMISTRY , *MONOCLONAL antibodies , *CELLS , *LIVER cells , *PLANT clones - Abstract
Nowadays, the major limit to the immunohistochemical (IHC) analysis of tissue PD-L1 is the high variability of the monoclonal antibodies commercially available. Aims of the present paper are to assess the best clone and the most suitable scoring for PD-L1 IHC determination on human hepatocellular carcinoma (HCC) among three commercially available clones, and to evaluate which PD-L1 clone is the best in predicting HCC aggressiveness in vivo. We built a tissue microarray (TMA) with 60 retrospective HCC cases, including the correspondent non-tumoral tissue. IHC was automatically performed using the following anti-PD-L1 clones: 28.8, SP142, and SP263. As results, we did not find any immunoreactivity for PD-L1 in both neoplastic and normal hepatocytes included in the TMA using the three antibodies. Positivity for PD-L1 was exclusively seen in inflammatory cells within the HCC tissue and in cirrhotic parenchyma. When a gold standard was assessed, the sensitivity of SP142, 28.8 and SP263 was 46 %, 54 % and 85 % respectively. Using the SP263 clone, the absolute number of PD-L1-positive inflammatory cells in the HCC cores was paired with the number of PD-L1-positive inflammatory cells in the corresponding non-tumoral tissue (P = 0.001). Finally, using SP263, the mean number of PD-L1-positive cells was 11.3 ± 12.6 in HCC from deceased patients, versus 4.7 ± 5.2 in alive patients (p = 0.039). SP263 is the most sensitive clone for PD-L1 IHC tissue determination in HCC, as well as the best antibody for the assessment of its biological behavior. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.